CXCL16 and metabolic syndrome: Moreover, pharmacological CXCL16 treatment abolished QGHXR-induced beneficial effects in the ethanol plus CCl4 mouse model, as evidenced by liver function biomarkers, dyslipidemia, and fibrotic indices.